Transplantation of allogeneic peripheral blood progenitor cells - A singlecentre experience

13 patients have been transplanted at Institute of Hematology and Blood Tra nsfusion since 1995 using allogeneic PBPC either alone or with bone marrow as a source of progenitor cells. All donors were G-CSF mobilised HLA identi cal family members. PBPC harvests were performed on D 4,5, (6) of G-CSF administration. The med ium content of TNC, CD34+, CD3+, CD4+and CD8+cells/kg b.w. of the recepient s in the grafts were: 13,1x10(8)(TNC), 11,4x10(6)(CD34+), 393x10(6)(CD3+) 243x10(6)(CD4+), 125x10 (6)(CD8+) The patients received either BuCy2 or CyTBI preparative regimen and Cyclosp orin A + short course of Methotrexate for GVHD profylaxis. Engraftment of ANC >500 was achieved by D+16 and PLT >20.000 by D+19. Three of ten evaluable patients developed acute and three of nine chronic GVHD. 8 patients survive with the longest follow up 776 days.